Algernon Pharmaceuticals Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Public

  • Employees
  • 1

Employees

  • Stock Symbol
  • AGN

Stock Symbol

  • Investments
  • 1

  • Share Price
  • $0.06
  • (As of Friday Closing)

Algernon Pharmaceuticals General Information

Description

Algernon Pharmaceuticals Inc is a clinical-stage drug development company focused on the disease areas of stroke, idiopathic pulmonary fibrosis and chronic cough. The company's business model is capital efficient and strives to deliver maximum shareholder value. Algernon's approach to drug discovery is based on the concept of drug repurposing. It operates in two reportable segments: the development of repurposed therapeutic drugs in Canada, and the facilitation of the Company's drug candidates into off-label phase II clinical trials (humans) in Australia.

Contact Information

Formerly Known As
Breathtec Biomedical
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Stock Exchange
CNQ
Corporate Office
  • 601 West Broadway
  • Suite 400
  • Vancouver, British Columbia V5Z 4C2
  • Canada

Algernon Pharmaceuticals Timeline

2021202220232024
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Algernon Pharmaceuticals Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.06 $0.06 $0.04 - $0.45 $1.2M 21.6M 47.4K -$0.21

Algernon Pharmaceuticals Financials Summary

In Thousands,
USD
TTM 30-Nov-2023 FY 2023 31-Aug-2023 FY 2022 31-Aug-2022 FY 2021 31-Aug-2021
EV 551 1,604 7,477 10,558
Revenue 0 0 0 0
EBITDA (3,978) (4,995) (4,731) (6,102)
Net Income (4,011) (5,031) (4,756) (6,092)
Total Assets 2,907 3,098 6,217 8,038
Total Debt 0 0 0 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Algernon Pharmaceuticals Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Algernon Pharmaceuticals‘s full profile, request access.

Request a free trial

Algernon Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Algernon Pharmaceuticals Inc is a clinical-stage drug development company focused on the disease areas of stroke, idiopa
Drug Discovery
Vancouver, Canada
1 As of 2022
00.000
000000000 00.000

000000

elit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupida
0000 000000000
Toronto, Canada
0 As of 0000
00.000
00.00 0000-00-00
000000&0 00.000

000000

quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequa
0000 000000000
New York, NY
00 As of 0000
00000
000000 - 000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Algernon Pharmaceuticals Competitors (9)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Mindset Pharma Corporate Backed or Acquired Toronto, Canada 0 00.000 000000&0 00.000
MindMed ( Pharmaceuticals and Biotechnology) Formerly VC-backed New York, NY 00 00000 000000 - 000 00000
GH Research Formerly VC-backed Dublin, Ireland 00 00000 00000000 00000
Voyager Therapeutics Corporation Cambridge, MA 000 00000 00000000 00000
Spark Therapeutics Formerly VC-backed Philadelphia, PA 000 00000 000000&0 00000
You’re viewing 5 of 9 competitors. Get the full list »

Algernon Pharmaceuticals Patents

Algernon Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-3206956-A1 Dmt salts and their use to treat brain injury Pending 29-Jan-2021 000000000
EP-4284364-A1 Dmt salts and their use to treat brain injury Pending 29-Jan-2021 000000000
CA-3155464-A1 Use of glutamate 2b receptor antagonists and sigma receptor agonsists as antitussives Pending 28-Oct-2019 0000000000
US-20220378769-A1 Use of glutamate 2b receptor antagonists and sigma receptor agonists as antitussives Pending 28-Oct-2019 0000000000
EP-4051276-A1 Use of glutamate 2b receptor antagonists and sigma receptor agonsists as antitussives Pending 28-Oct-2019 A61K31/445
To view Algernon Pharmaceuticals’s complete patent history, request access »

Algernon Pharmaceuticals Executive Team (10)

Name Title Board Seat Contact Info
Christopher Moreau Chief Executive Officer & Director
Ahmad Khalil Ph.D Chief Medical Officer & Executive Vice President
Christopher Bryan Ph.D Vice President Research & Operations
James Kinley Chief Financial Officer & Director
Rajpaul Attariwala Ph.D Director
You’re viewing 5 of 10 executive team members. Get the full list »

Algernon Pharmaceuticals Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Algernon Pharmaceuticals Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Algernon Pharmaceuticals‘s full profile, request access.

Request a free trial

Algernon Pharmaceuticals Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Nash Pharmaceuticals 22-Oct-2018 0000000000 00.000 Drug Discovery 000000000
To view Algernon Pharmaceuticals’s complete acquisitions history, request access »

Algernon Pharmaceuticals Subsidiaries (1)

Company Name Industry Location Founded
Algernon Pharmaceuticals (NP-120 Ifenprodil Research Program) Buildings and Property Vancouver, Canada
To view Algernon Pharmaceuticals’s complete subsidiaries history, request access »

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »